Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups
Naunyn-Schmiedeberg's Archives of Pharmacology · 29.10.2026
DOI: 10.1007/s00210-026-06018-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 29.10.2026. Verfasst von Zifan Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Sumatriptan is a 5-hydroxytryptamine 1B/1D receptor agonist for acute migraine. Reduced organic cation transporter 1 (OCT1) function is associated with increased sumatriptan exposure, but its quantitative contribution to pharmacokinetic variability remains unclear. The aim of the study is to develop a whole-body physiologically based pharmacokinetic (PBPK) model describing sumatriptan PK across OCT1 functional groups and explore an exposure-matched candidate dose. A 50-mg mixed-genotype base model was developed from three clinical studies and extrapolated to 25 and 100 mg without reestimating drug-specific parameters. OCT1 functional differences were represented by changes in the effective OCT1-mediated hepatic uptake capacity ( V _max). Individuals with 0 active OCT1 alleles were compared with those with 1 or 2 active alleles. Oral doses of 20, 25, and 30 mg were explored in the 0-active-allele group using a predefined exposure-matching range of 0.80–1.25 for C _max and AUC_0-9 h. Across 50-mg studies, geometric mean fold errors were 1.25 for C _max, 1.07 for AUC_0-12 h, and 1.12 for T _max. Across 25- and 100-mg studies, predicted-to-observed ratios ranged from 0.65 to 1.50. After 50 mg, predicted C _max and AUC_0-9 h ratios for the 0-active-allele group relative to the 1-or-2-active-allele group were 1.81 and 1.82, compared with observed ratios of 1.77 and 2.20. Both 25 and 30 mg in the 0-active-allele group met the predefined exposure-matching criterion relative to 50 mg in the 1-or-2-active-allele group, whereas 20 mg did not. The PBPK model quantified OCT1-related variability in sumatriptan disposition and supported 25 mg as a clinically feasible exploratory candidate for prospective evaluation in the 0-active-allele group. Graphical Abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
- School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. zhengl@ahmu.edu.cn.
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. huwei@ahmu.edu.cn.
ORCID-Profile: Liang Zheng
Zitieren
APA
Ji, Z., Dai, T., Xu, Y., Wang, Z., Zhang, Q., Zheng, L., & Hu, W. (2026). Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-06018-w
Vancouver
Ji Z, Dai T, Xu Y, Wang Z, Zhang Q, Zheng L, et al. Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-06018-w
BibTeX
@article{Ji2026,
author = {Ji, Zifan and Dai, Tingting and Xu, Yixinyue and Wang, Zilong and Zhang, Qian and Zheng, Liang and Hu, Wei},
title = {Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-06018-w}
}
EUVIMED